Inosine pranobex in the treatment of HIV infection: A review

Simone, C. De; Famularo, Giuseppe; Tzantzoglou, Sonia; Moretti, Sonia; Jirillo, Emilio

doi:10.1016/0192-0561(91)90120-v

Cited by 21 publications

(6 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5 An effective delay in the progression of HIV infection in asymptomatic HIV-positive patients taking the drug has also been observed. 6 Available data about the therapeutic efficacy of inosine pranobex in mucocutaneous herpes are controversial. The aim of this study was to explore the efficacy and tolerance of the oral inosine pranobex in suppression of recurrent herpes labialis (RHL) and recurrent herpes genitalis (RHG) in comparison with acyclovir.…”

Section: Introductionmentioning

confidence: 99%

“…With an immunomodulatory effect, it has been shown to exert antiviral and antitumor activities in vivo and can be used to treat orolabial herpes, subacute sclerosing panencephalitis, influenza and type B viral hepatitis . An effective delay in the progression of HIV infection in asymptomatic HIV‐positive patients taking the drug has also been observed . Available data about the therapeutic efficacy of inosine pranobex in mucocutaneous herpes are controversial.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Multicenter randomized study of inosine pranobex versus acyclovir in the treatment of recurrent herpes labialis and recurrent herpes genitalis in Chinese patients

You

Wang

et al. 2015

The Journal of Dermatology

View full text Add to dashboard Cite

The objective of the study is to evaluate the efficacy and safety of oral inosine pranobex as compared with acyclovir in the treatment of recurrent herpes labialis (RHL) and recurrent herpes genitalis (RHG). A multicenter double-blind, double-dummy, randomized, controlled, parallel group trial was conducted in 144 patients with RHL and 144 RHG. Patients were assigned to treatment in one of two groups: (i) inosine pranobex group (active inosine pranobex, 1 g four times daily, and acyclovir placebo); or (ii) acyclovir group (active acyclovir, 200 mg five times daily, and inosine pranobex placebo). The total symptom score (TSS) of patients with RHL did not differ in the inosine pranobex and acyclovir group on the 3rd or 7th day of treatment. There was also no difference in the efficacy rates between the two groups. No difference of TSS was observed between patients with RHG taking inosine pranobex and acyclovir on days 3 or 5 of the treatment, respectively. The short-term clinical recurrence rate of RHG at 3-month follow-up was much lower in the inosine pranobex group than acyclovir group. The incidence of hyperuricemia was higher in the inosine pranobex group than acyclovir group. In conclusion, inosine pranobex was as effective as acyclovir in treating RHL and RHG with significantly greater reduction of the short-term recurrence rate of herpes genitalis at 3-month follow up. Long-term recurrence rates at 6 months or longer remain to be determined. Hyperuricemia should be monitored during the treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Multicenter randomized study of inosine pranobex versus acyclovir in the treatment of recurrent herpes labialis and recurrent herpes genitalis in Chinese patients

You

Wang

et al. 2015

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…Inosiplex was found to have a broad spectrum of antiviral activity, including alleviating symptoms of subacute sclerosing panencephalitis, symptomatic subclinical human papillomavirus infection, and cervical condylomata acuminata because of genital human papillomavirus [2] , [3] , [4] . Inosiplex could also delay the progression of HIV infection to overt AIDS [5] . In addition, inosiplex has been employed as an immunoregulating agent for the treatment of immunopathological disorders, such as rheumatoid arthritis and alopecia areata [6] , [7] .…”

Section: Introductionmentioning

confidence: 99%

Pharmacokinetic study of inosiplex tablets in healthy Chinese volunteers by hyphenated HPLC and tandem MS techniques

Chen

Zhang

Que

et al. 2013

Journal of Pharmaceutical Analysis

View full text Add to dashboard Cite

Inosiplex is a compound formulation composed of inosine and p-acetaminobenzoic acid (PABA) salt of N,N-dimethylamino-2-propanol (DIP). This study was to investigate the clinical plasma pharmacokinetic properties of DIP and PABA after single and multiple oral doses of inosiplex tablets in healthy Chinese volunteers. The established LC/MS/MS method for plasma DIP determination had a linear range of 0.02–10 µg/mL, and the HPLC method for plasma PABA determination had a linear range of 0.05–40 µg/mL. Linear pharmacokinetic characteristics were found with single oral doses of 0.5, 1.0 and 2.0 g. No obvious accumulation effects were observed for DIP and PABA.

show abstract

“…(30) is a novel compound. (31), also known as Acedoben, is to be found as a complex containing the salt of 4-acetylaminobenzoic acid with N,N-dimethylaminopropan-2-ol and inosine in a 3 : 1 ratio in Inoprinosine (or Inosiplex, or Inosine pranobex) [201], an antiviral drug useful for retarding neurological deterioration and prolonging life in patients with slowly progressive subacute sclerosing panencephalitis [202], and for the treatment of HIV infections [203], or as an immunomodulatory agent in the therapy of other infections [204]. Isoprinosine's possible mechanism of action in AIDS patients by preventing Pneumocystis carinii pneumonia relies on the ability of 4acetylaminobenzoic acid to inhibit dihydropteroate synthetase [205].…”

Section: -Diethylaminoethyl 4-aminobenzoate (Procaine)mentioning

confidence: 99%

Drug Evolution Concept in Drug Design: 2. Chimera Method

Roman¹,

Popek²,

Lazar³

et al. 2006

View full text Add to dashboard Cite

The drug evolution method represents a novel approach towards efficient rational drug design by implementing the drug evolution concept to the creation and development of general chemical libraries with the purpose of allowing the identification of drug candidates with improved odds and lesser costs than the traditional drug design strategies. As another example of successful translation of the biological evolution into chemical evolution, the chimera method comprises the grafting of selected building blocks, identified through a basic search within a drug library, onto the same substitution sites on a rationally chosen scaffold. The method allows the creation of a library containing both drugs and prospective drug candidates without any priorly required knowledge on the pursued disease or molecular target. Two libraries having scaffolds derived from para-aminobenzoic acid and salicylic acid have exemplified the application of the chimera method. The validation of the method has been achieved through the high number of recognized drugs within the library, which exhibit in the same time a wide variety of therapeutic activities and interact with a broad spectrum of molecular targets. The drug-enriched chimera libraries are expected to provide a highly efficient access to novel drug candidates whose unspecified therapeutic effects should be further revealed through high-throughput screening.

show abstract

Inosine pranobex in the treatment of HIV infection: A review

Cited by 21 publications

References 36 publications

Multicenter randomized study of inosine pranobex versus acyclovir in the treatment of recurrent herpes labialis and recurrent herpes genitalis in Chinese patients

Multicenter randomized study of inosine pranobex versus acyclovir in the treatment of recurrent herpes labialis and recurrent herpes genitalis in Chinese patients

Pharmacokinetic study of inosiplex tablets in healthy Chinese volunteers by hyphenated HPLC and tandem MS techniques

Drug Evolution Concept in Drug Design: 2. Chimera Method

Contact Info

Product

Resources

About